Does below-optimal 1,5-anhydroglucitol suggest post-meal glucose excursions?

A below-optimal 1,5-anhydroglucitol (1,5-AG) result is consistent with, but does not establish, recent post-meal hyperglycemic excursions. Its interpretation depends heavily on renal glucose handling and medication use.

Clinical interpretation

• 1,5-AG reflects glycemic exposure over roughly the preceding 1–2 weeks and is particularly responsive to glucose elevations that exceed the renal threshold and produce glycosuria.
• In adults with type 2 diabetes and HbA1c 6.5–8%, lower 1,5-AG correlated with higher post-meal glucose peaks (r = −0.54) and greater CGM time/exposure above 180 mg/dL (r = −0.45).
• Thus, a low value reasonably leaves open the possibility of repeated or sufficiently sustained post-meal elevations, even if HbA1c does not appear markedly elevated. It cannot determine the timing, height, duration, or frequency of any individual glucose peak.

Mechanism and confounders

• Filtered 1,5-AG is normally almost completely reabsorbed in the proximal renal tubule. When plasma glucose rises beyond an individual renal threshold—often approximately 160–180 mg/dL—glucose appears in urine and competitively reduces 1,5-AG reabsorption.
• Increased urinary 1,5-AG loss then lowers its circulating concentration. Therefore, the marker is an indirect signal of recent glycosuric hyperglycemia, not a direct measurement of post-meal glucose.
• SGLT2 inhibitors can lower serum 1,5-AG independently of improved glycemia by intentionally increasing urinary glucose; FDA labeling cautions that 1,5-AG is unreliable during such treatment. Kidney/tubular disorders, altered renal thresholds, and pregnancy can also confound interpretation.

Bottom line

• A below-optimal 1,5-AG supports the possibility of recent glucose excursions that crossed the renal threshold, including post-meal peaks, but confirmation requires CGM or targeted post-meal glucose testing—particularly after accounting for SGLT2-inhibitor use and renal factors.